Two Sigma Investments LP trimmed its stake in shares of SI-BONE, Inc. (NASDAQ:SIBN - Free Report) by 48.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 69,750 shares of the company's stock after selling 66,105 shares during the quarter. Two Sigma Investments LP owned about 0.17% of SI-BONE worth $978,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds have also made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in SI-BONE by 4.4% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,373 shares of the company's stock valued at $328,000 after purchasing an additional 988 shares during the period. Invesco Ltd. lifted its stake in SI-BONE by 8.9% in the fourth quarter. Invesco Ltd. now owns 17,203 shares of the company's stock valued at $241,000 after buying an additional 1,413 shares during the last quarter. Rhumbline Advisers lifted its stake in SI-BONE by 3.0% in the fourth quarter. Rhumbline Advisers now owns 57,621 shares of the company's stock valued at $808,000 after buying an additional 1,683 shares during the last quarter. Barclays PLC grew its position in shares of SI-BONE by 2.7% during the fourth quarter. Barclays PLC now owns 99,212 shares of the company's stock worth $1,391,000 after acquiring an additional 2,589 shares during the last quarter. Finally, Alliancebernstein L.P. grew its position in shares of SI-BONE by 6.2% during the fourth quarter. Alliancebernstein L.P. now owns 55,750 shares of the company's stock worth $782,000 after acquiring an additional 3,250 shares during the last quarter. 98.11% of the stock is currently owned by institutional investors and hedge funds.
SI-BONE Price Performance
SIBN stock traded down $0.04 during trading on Monday, hitting $18.86. The company had a trading volume of 293,360 shares, compared to its average volume of 383,088. The business has a 50 day moving average of $16.10 and a 200 day moving average of $15.56. The firm has a market capitalization of $803.72 million, a price-to-earnings ratio of -20.50 and a beta of 0.94. The company has a current ratio of 8.25, a quick ratio of 7.22 and a debt-to-equity ratio of 0.22. SI-BONE, Inc. has a fifty-two week low of $11.70 and a fifty-two week high of $20.05.
SI-BONE (NASDAQ:SIBN - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The company reported ($0.15) earnings per share for the quarter, topping analysts' consensus estimates of ($0.24) by $0.09. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. The company had revenue of $47.29 million during the quarter, compared to analyst estimates of $45.13 million. As a group, research analysts predict that SI-BONE, Inc. will post -0.78 earnings per share for the current year.
Wall Street Analyst Weigh In
SIBN has been the topic of several recent research reports. Cantor Fitzgerald reissued an "overweight" rating and set a $25.00 target price on shares of SI-BONE in a research note on Tuesday, May 6th. Truist Financial boosted their price objective on SI-BONE from $20.00 to $22.00 and gave the stock a "buy" rating in a research report on Tuesday, May 6th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $24.00 price objective on shares of SI-BONE in a report on Tuesday, May 6th.
View Our Latest Stock Report on SI-BONE
Insider Buying and Selling
In related news, CFO Anshul Maheshwari sold 9,585 shares of the stock in a transaction on Friday, May 16th. The stock was sold at an average price of $19.76, for a total value of $189,399.60. Following the completion of the transaction, the chief financial officer now owns 224,507 shares in the company, valued at $4,436,258.32. This trade represents a 4.09% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Jeffrey W. Dunn sold 3,377 shares of the business's stock in a transaction dated Thursday, June 5th. The stock was sold at an average price of $19.05, for a total value of $64,331.85. Following the sale, the director now owns 17,354 shares in the company, valued at approximately $330,593.70. The trade was a 16.29% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 95,942 shares of company stock valued at $1,734,203 over the last three months. Company insiders own 4.00% of the company's stock.
SI-BONE Company Profile
(
Free Report)
SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.
Further Reading
Before you consider SiBone, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SiBone wasn't on the list.
While SiBone currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
